MILK LEVEL OF CEFTIZOXIME FOLLOWING SINGLE INTRAMUSCULAR DOSING OF CEFTRIAXONE WITHOUT AND WITH ORAL ADMINISTRATION OF FIBROSIN® AND ITS EFFECT ON MILK ENZYME ACTIVITY IN GOAT

The veterinarians frequently use ceftriaxone intramuscularly in treatment of mastitis. Fibrosin® , a polyherbal drug is also commonly used as supportive therapy for let down of milk during mastitis. The present study was conducted to determine milk level of ceftizoxime, a major active metabolite of ceftriaxone and its effect on milk enzyme activity in lactating goats following single dose intramuscular administration of ceftriaxone (@ 50 mg / kg body weight) with or without one hour prior to oral administration of polyherbal drug (1.9 gm). Twelve clinically healthy lactating Black Bengal goats were divided into two groups (namely Group I, group II) each containing six goats. A single intramuscular dose of ceftriaxone was administered at 50 mg/kg body weight to each goat of group-I only, while a total dose of 1.9 gm of polyherbal drug was administered orally to each goat of group-II before one hour of cefriaxone administration. Milk concentration of ceftriaxone and ceftizoxime were analyzed by HPLC. Ceftizoxime was detected in milk from 5 minutes to 24 hours post dosing following single intramuscular dose of ceftriaxone without Fibrosin® administration. However, neither ceftriaxone nor ceftizoxime could be detected in milk following single intramuscular dosing of ceftriaxone with Fibrosin® administration. Milk alkaline phosphatase and catalase activity as well as reduced glutathione level did not differ significantly between group I and group II animals. Milk alkaline phosphatase activity was increased markedly following intramuscular administration of ceftriaxone indicating mammary tissue damage. Thus the present study showed that Fibrosin® should be avoided with intramuscular ceftriaxone for treatment of mastitis due to unavailability of ceftriaxone / ceftizoxime in milk. However, oral administration of Fibrosin can be preferred in other bacterial infections with concurrent administration of intramuscular ceftriaxone as it reduces milk residue of ceftizoxime.